Oncology Supplemental      

FOI REFERENCE: 24523  FOI DATE: 14^th November 2024    

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• Atezolizumab (Tecentriq) 8 Patients
• Durvalumab (Imfinzi) 0 Patients
• Nivolumab (Opdivo) 2 Patients
• Pembrolizumab (Keytruda) 18 Patients
• Chemotherapy 59 Patients
• Radiotherapy 0 Patients
• Chemotherapy AND Radiotherapy 0 Patients
• Osimertinib 11 Patients

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

• CAPOX (Capecitabine with Oxaliplatin) 2 Patients
• FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 3 Patients
• Lonsurf (Trifluridine – tipiracil) 0 Patients
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 Patients
• Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 1 Patient
• Any other systemic anti-cancer therapy
• Palliative care only 6 Patients
• Zolbetuximab (Vyloy) 0 Patients